Dr. Kaslow is our vice president of Product Development. Photo: Merck.
Vice President, Product Development and Interim Program Leader, Drug Development
David Kaslow, MD, oversees PATH’s five product development programs—Drug Development, the Malaria Vaccine Initiative (MVI), Technology Solutions, Vaccine Access and Delivery, and Vaccine Development—as well as our work in China, which focuses on product development activities. He currently is also the interim leader of our drug development program.
Dr. Kaslow has more than 25 years of experience in vaccine research and development. Before joining PATH in 2012 as director of MVI's work to drive the development of safe and effective vaccines against malaria, he held key advisory positions with MVI and the Bill & Melinda Gates Foundation related to malaria vaccines. Prior to that, he oversaw project leadership and management of Merck Research Laboratories’ vaccine pipeline and founded the Malaria Vaccine Development Unit at the National Institutes of Health.
As a basic research scientist, Dr. Kaslow completed the molecular cloning and characterization of several proteins involved in malaria parasite sexual development. He also has directed product development, including field studies, of several malaria vaccine candidates. Outside the malaria field, Dr. Kaslow has contributed to the vaccine application of tools originally developed for gene therapy. He holds or coholds more than a dozen patents and has published more than 150 scientific papers.
Dr. Kaslow received his medical degree from the University of California, San Francisco.